Advanced search×

Therapeutic response of rosacea to dobesilate.

Pedro Cuevas and J M Arrazola

European Journal of Medical Research 10(10):454-6 (2005) PMID 16287608

Despite an incomplete understanding of the pathogenesis of rosacea, therapeutic modalities continue to expand. The principal subtype of rosacea includes erythematotelangiestatic rosacea, which is characterized by uncontrolled angiogenesis. Angiogenic growth factors such as fibroblast growth factors (FGF) and vascular endothelial growth factor (VEGF) are currently targets of intense effort to inhibit deregulated blood vessel formation in diseases such as cancer. Here we report a 33-years-old woman with erythematotelangestatic rosacea who responds to a daily treatment of topically applied dobesilate, an inhibitor of FGF, with an improvement in erythema and telangectasia after two weeks. Thus, dobesilate might be useful in the treatment of rosacea and other diseases that depend on pathologic angiogenesis.

Version: za2963e q8zaf q8zba q8zc3 q8zd3 q8ze6 q8zff q8zg8
Buy PDF

Similar articles you may find interesting…

  1. Targeting cAMP in chronic lymphocytic leukemia: a pathway-dependent approach for the treatment of leukemia and lymphoma.
    Fiona Murray and Paul A Insel

    Expert Opin Ther Targets (2013) PMID 23647244

    Cyclic AMP (cAMP) promotes growth arrest and/or apoptosis of various types of lymphoma, in particular chronic lymphocytic leukemia (CLL). These responses have spurred the interest in developing agents that increase cAMP to treat such malignancies and to identify mechanisms of the responses. Areas co...
    Buy PDF
  2. Chain-Shattering Polymeric Therapeutics with On-Demand Drug-Release Capability.
    Yanfeng Zhang, Qian Yin, and Jianjun Cheng

    Angew Chem Int Ed Engl (2013) PMID 23650111

    Trigger happy: Trigger-responsive chain-shattering polymeric therapeutics (CSPTs) were prepared by condensation polymerization of a UV- or hydrogen peroxide-responsive domain and a drug as co-monomers. Drug release can be started and stopped by starting and stopping the trigger treat...
    Buy PDF
  3. The Steroid Receptor Coactivator-3 Is Required for the Development of Castration-resistant Prostate Cancer.
    Jean Ching-Yi Tien, Zhaoliang Liu, and Jianming Xu

    Cancer Res (2013) PMID 23650284

    We documented elevated SRC-3 in human CRPC and in PTEN-negative human CaP. Patients with high SRC-3 and undetectable PTEN exhibited decreased recurrence-free survival. To explore the causal relationship in these observations, we generated mice in which both Pten and SRC-3 were inactivated in prostat...
    Buy PDF